![Consistent reversal of DOAC effect by andexanet alfa on plasma thrombin generation. (A-C) Assessed thrombin generation in NPP with 600 nM rivaroxaban and 0 to 19 200 nM andexanet alfa (trigger 5 pM TF). Shown are representative traces (A) and the parameters lag time (B) and thrombin peak level (C). Further, assessed TG in NPP with 300 nM edoxaban (D-F) or 400 nM apixaban (G-I) and at indicated concentration of andexanet alfa (nM). Shown are representative traces (D,G), lag time (E,H), and thrombin peak level (G,I). Control condition represents absence of DOAC or andexanet alfa. Means ± standard deviation (SD) (n = 3). ∗P < .05, ∗∗P < .01, ∗∗∗P < .001 (1-way analysis of variance [ANOVA]). N.S, not significant.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodvth/2/4/10.1016_j.bvth.2025.100100/2/bvth_vth-2025-000355-gr1.jpeg?Expires=1764949062&Signature=Bk5WIH4znS9evDs5f0OjmbKL39OqdPgOYjej-pyocUvb6zbHvEu-kXi376ENnb18it8q6sG4i4CS8~cHi8JB3NiqHxC1J7ECczJo3PTTB84gm5Sap3zKdP84u6qqu5pxR8BH1J27p2hat5~TZ8Ncqhg~XWHYViaHcPnSpet~SFZ-06qk~~XOzGrdTEmKm2YayOAZ0~xKKqYK~Lq-0qmkofUJZ9zZobv1mBdHWZb9fviO3pEmeYK7BXgJ5mUzsWunJphpziIAzNfnlj9i5xEKdzcs296BMgk90T91Lct5sVL6lMOmv4rnnw7XdRA4Q6a7sz2U0VbTJ3u9lHqiX0zUaw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Figure 1.
Consistent reversal of DOAC effect by andexanet alfa on plasma thrombin generation. (A-C) Assessed thrombin generation in NPP with 600 nM rivaroxaban and 0 to 19 200 nM andexanet alfa (trigger 5 pM TF). Shown are representative traces (A) and the parameters lag time (B) and thrombin peak level (C). Further, assessed TG in NPP with 300 nM edoxaban (D-F) or 400 nM apixaban (G-I) and at indicated concentration of andexanet alfa (nM). Shown are representative traces (D,G), lag time (E,H), and thrombin peak level (G,I). Control condition represents absence of DOAC or andexanet alfa. Means ± standard deviation (SD) (n = 3). ∗P < .05, ∗∗P < .01, ∗∗∗P < .001 (1-way analysis of variance [ANOVA]). N.S, not significant.
